Vigil Neuro
Bhaumik A. Pandya has a strong background in chemistry, with extensive experience working in various pharmaceutical and research companies. Currently holding a senior director position at Vigil Neuroscience, Bhaumik previously served as a principal scientist at Alnylam Pharmaceuticals and held senior roles at Amgen, Yumanity Therapeutics, Cubist Pharmaceuticals, Concert Pharmaceuticals, and The Broad Institute of MIT & Harvard. Bhaumik earned a Doctorate in Chemistry from Boston College and a Bachelor of Science in Chemistry from The College of New Jersey.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.